952490-01-6

Upstream product

• 288385-88-6 4-fluoro-2-methyl-1H-indol-5-ol 
• 872206-49-0 4-chloro-5-methylpyrrolo[1,2-f ][1,2,4]triazin-6-yl pivalate 
• 771-69-7 2,3,4-trifluoronitrobenzene 
• 872206-47-8 C₁₂H₁₅N₃O₃ 
• 1022112-32-8 2-(2,3-difluoro-6-nitrophenyl)-3-oxobutanoic acid ethyl ester 
• 427878-70-4 ethyl 4-hydroxy-5-methylpyrrolo[2,1-f ][1,2,4]-triazine-6-carboxylate 
• 121247-16-3 1-(2,3-difluoro-6-nitrophenyl)propan-2-one 
• 288385-99-9 1-(2-fluoro-3-methoxy-6-nitrophenyl)propan-2-one 
• 621685-54-9 C₈H₉N₃O₂ 
• 872206-45-6 C₇H₇N₃O₂ 
• 621685-55-0 C₈H₇N₃O₂ 
• 872206-43-4 C₁₀H₁₃N₃O₂ 
• 649736-31-2 1-(2-fluoro-3-hydroxy-6-nitrophenyl)propan-2-one 

Relevant academic research and scientific papers

Commercial synthesis of a pyrrolotriazine-fluoroindole intermediate to brivanib alaninate: Process development directed toward impurity control

The development of a practical, commercial process for the preparation of 4-fluoro-2-methyl-indol-5-ol and its subsequent coupling with a pyrrolotriazine to form an advanced intermediate of the oncology therapy brivanib alaninate is described. A key aspect is the multikilogram-scale preparation of the fluoroindole intermediate from trifluoronitrobenzene and the subsequent coupling while achieving impurity minimalization. As brivanib alaninate is a high-dose drug, the synthesis of highquality API with low levels of impurities is critical.

PROCESS FOR THE PREPARATION OF [(1R), 2S]-2-AMINOPROPIONIC ACID 2-[4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY]-1-METHYLETHYL ESTER

The invention relates to an improved process for preparing [(1R),2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester of the formula: Compound I has been shown to be useful f